EurekAlert!

Trojan Horse in Water: Amoebae as carriers for human Norovirus and Adenovirus

Living Amoebae: Protozoa as Potential Reservoirs and Transport Vessels for human Norovirus and Adenovirus,” published in ...
American Council on Science and Health

Another Norovirus Biotech Skyrockets: Hype or Hope?

The stock-trading website Raging Bull just gave Cocrystal Pharma, a clinical-stage biotech, a big thumbs up for its ...

COCP: CDI-988 Showcased at Calicivirus Conference; Direct Offering Raises Up to $13 Million…

COCP READ THE FULL COCP RESEARCH REPORT Business Update CDI-988 Overview Presented at Calicivirus Conference On September 12, ...

Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Confer…

Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that President and co-CEO Sam Lee, PhD discussed the scientific foundation ...
TMCnet

Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference

BOTHELL, Wash., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that President and co-CEO Sam Lee, PhD discussed the scientific foundation and clinical progress with ...
Clinical Trials Arena on MSN

Cocrystal Pharma’s norovirus antiviral study receives FDA clearance

C ocrystal Pharma has received investigational new drug (IND) clearance from the US Food and Drug Administration (FDA) to conduct a Phase Ib challenge trial of pan-viral 3CL protease inhibitor CDI-988 ...
TMCnet

Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and ...

There are currently no approved vaccines or treatments for norovirus infection Cocrystal’s CDI-988 is the first antiviral for the potential prevention and treatment of viral gastroenteritis caused by ...